Today Stories

PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today published its 2022 Environmental, Social, and Governance (ESG) Report, which details the Company’s goals, strategies, and performance across its four ESG focus areas including ethics, integrity, and quality; health equity and access to healthcare; global inclusion and diversity; and environmental sustainability. As a leading biopharmaceutical company, Bristol Myers Squibb is committed to discovering, developing, and delivering innovative medicines that help patients prevail over serious diseases. The Company’s ESG strategy is embedded in its mission and builds on a legacy of comprehensive and global sustainability efforts that seek to drive business value and positively impact patients, employees, communities, and th…

23 August 2023: Kadans Science Partner (“Kadans”) is set to welcome AviadoBio to its recently completed wet lab innovation and flexible workspace centre at 20 Water Street in Canary Wharf. AviadoBio, a pioneering gene therapy company developing and delivering transformative medicines for neurodegenerative disorders, will establish laboratory and office presence at the Innovation Centre. AviadoBio will begin working at Kadans’ London Innovation Centre following the recent completion of their wet-lab Innovation Centre at levels four and five at 20 Water Street. The company will be joining the Kadans’ growing European ecosystem of over 450 tenants including Cytiva, Akamis Bio, GeneFirst and Sherlock Bioscience. Lisa Deschamps, CEO of AviadoBio, said: “We are very excited about our new partner…

Strategic Partnership Aims to Revolutionize Cancer Screening and Enhance Healthcare Outcomes, Bringing Innovative Genetic Testing Solutions to Individuals Across Poland BERKELEY, US – MAINZ, Germany – August 22, 2023 — Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”) , a molecular genetics diagnostic company specializing in the early detection of cancer, announces the commercial launch of ColoAlert® in Poland, made possible through a strategic collaboration with testDNA Sp. z o. o. Sp. K (“testDNA”). The partnership marks another significant step forward in providing new and innovative testing options to underserved populations in the battle against colorectal cancer (“CRC”). ColoAlert®, Mainz Biomed's flagship product is a user-friendly and highly effective at-home screenin…

Wealth of heart failure data supports medical guideline updates and underscores commitment to improving patient outcomes AstraZeneca will present 19 abstracts, including 10 oral presentations and five late-breaking presentations, at the European Society of Cardiology (ESC) Congress from 25-28 August 2023, which includes data highlighting the opportunities for improved management in heart failure (HF), and AstraZeneca’s leadership across the interconnectedness of chronic diseases. Among these abstracts will be sub-analyses from the DELIVER trial – a trial that has been pivotal in informing updates to medical guidelines. Notably, new late-breaking data from a pooled analysis of DELIVER and DAPA-HF trials assess the efficacy of Forxiga (dapagliflozin) versus placebo in HF patients whose…

AQUIPTA® (atogepant) is the first and only once-daily oral calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) in the European Union (EU) approved for the prophylaxis of migraine in adults who have four or more migraine days per month Approval is based on two pivotal Phase 3 studies that demonstrated statistically significant reduction in mean monthly migraine days with AQUIPTA compared to placebo in adult patients with both chronic and episodic migraine The approval expands AbbVie's portfolio of therapies for adult patients in the EU across migraine frequencies, including episodic and chronic migraine NORTH CHICAGO, Ill., Aug. 17, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the European Commission has approved AQUIPTA® (atogepant) for the prophylaxis of…

– Collaboration Combines Gilead’s Oncology and Inflammation Expertise and Tentarix ’s Tentacles™ Platform – – Gilead Receives Exclusive Rights to Acquire Novel Therapies From this Collaboration – FOSTER CITY, Calif. & SAN DIEGO--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq:GILD) and Tentarix Biotherapeutics today announced that the companies established three multi-year collaborations leveraging Tentarix’s proprietary Tentacles™ platform to discover and develop multi-functional, conditional protein therapeutics for oncology and inflammatory diseases. Designed to enhance both therapeutic benefit and safety, these molecules have the potential to conditionally target immune cells related to disease pathways without activating other immune cells that may create adverse events. “At Gil…

INDIANAPOLIS, Aug. 14, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Sigilon Therapeutics, Inc. (NASDAQ: SGTX). The acquisition allows Lilly to continue researching and developing encapsulated cell therapies, including SIG-002, for the treatment of type 1 diabetes. "Make life better – that's the phrase that guides everything we do at Lilly," said Ruth Gimeno, Ph.D., group vice president, diabetes, obesity and cardiometabolic research at Lilly. "We are excited to welcome our new colleagues from Sigilon to Lilly; together, we will strive to provide solutions for people living with type 1 diabetes that absolves them of constant disease management, and advance Sigilon's technology for patients." The Offer and the Merger A…

INDIANAPOLIS, Aug. 14, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Versanis Bio. The acquisition expands Lilly's portfolio to include Versanis' lead asset, bimagrumab, which is currently being assessed in a Phase 2b study alone and in combination with semaglutide in adults living with overweight or obesity. "Combining our current incretin portfolio, including tirzepatide, with activin receptor blockers such as bimagrumab, could be the next major step in innovative treatments for those living with cardiometabolic diseases, like obesity," said Ruth Gimeno, Ph.D., group vice president, diabetes, obesity and cardiometabolic research at Lilly. "The wealth of knowledge that our new colleagues from Versanis will bring to L…

The two organizations are joining forces to develop pioneering AI-based solutions for efficient chemical synthesis planning to accelerate the development of novel pharmaceuticals. COLUMBUS, Ohio & WARSAW, Poland--(BUSINESS WIRE)--CAS, a division of the American Chemical Society specializing in scientific information solutions, and Molecule.one, a tech-bio leader in AI-based solutions for pharmaceutical chemistry, have established a strategic collaboration focused on the joint development of computer-aided synthesis design technologies to accelerate scientific breakthroughs in early-stage drug discovery and aid chemists in the discovery of novel small molecules. Leveraging their existing technologies and expertise, including Molecule.one’s proprietary generative deep learning models and…

Bagsværd, Denmark and Montreal, Canada, 10 August 2023 – Novo Nordisk A/S and Inversago Pharma today announced that Novo Nordisk has agreed to acquire Inversago for up to 1.075 billion US dollars in cash if certain development and commercial milestones are achieved. Inversago Pharma is a private, Montreal-based developer of CB1 receptor-based therapies for the potential treatment of obesity, diabetes and complications associated with metabolic disorders. The acquisition of Inversago includes the company’s lead development asset INV-202, an oral CB1 inverse agonist. INV-202 is designed to preferentially block the receptor protein CB1 – which plays an important role in metabolism and appetite regulation – in peripheral tissues such as adipose tissues, the gastro-intestinal tract, the kidneys…

INDIANAPOLIS, Aug. 9, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of DICE Therapeutics, Inc. (NASDAQ: DICE). The acquisition expands Lilly's immunology portfolio to include DICE's novel oral therapeutic candidates, including oral IL-17 inhibitors currently in clinical development, to treat chronic diseases in immunology. "Since our founding nearly 150 years ago, we've strived to make life better for people around the world – but we know that to achieve this goal, we have to bring the brightest minds to Lilly," said Ajay Nirula, Ph.D., senior vice president of immunology at Lilly. "With the passion and expertise of our new colleagues from DICE, we look forward to continuing our pursuit of discovering and delivering life…

STORM Therapeutics Ltd. (STORM), a clinical stage biotechnology company focused on discovering and developing novel small molecule therapies targeting RNA modifying enzymes (RMEs) for oncology and other diseases, is pleased to announce that it will be presenting the discovery of its lead clinical candidate, STC-15, which is an orally bioavailable and highly selective METTL3 inhibitor, at the American Chemical Society (ACS) Fall 2023 Conference, in San Francisco, California on the 13-17 August 2023. The presentation entitled “Discovery of STC-15, an orally bioavailable, highly selective METTL3 inhibitor for the treatment of AML and solid tumours: The first molecule specifically targeting an RNA methyltransferase enzyme to enter clinical development” will detail the Company’s discovery effor…

Research collaboration leverages bit.bio’s machine learning-powered discovery platform to identify transcription factor (TF) combinations for reprogramming induced pluripotent stem cells (iPSCs) into Tregs. / Agreement includes option for BlueRock to license TF combinations emerging from the collaboration as well as an option to license bit.bio’s opti-oxTM precision cell programming technology for the manufacture and subsequent development of iPSC-derived Treg cell therapies. / bit.bio receives an upfront payment from BlueRock and is eligible to receive milestone payments and royalties on worldwide sales of all therapies resulting from the collaboration. Cambridge, MA USA 7:30 am and Cambridge, UK 12:30pm, August 3, 2023: BlueRock Therapeutics LP, a clinical stage cell t…

Envisioning the future of regulatory and medical writing, CAPTIS Copilot leverages cutting-edge AI models for the Medical Device and Diagnostic industry. CHICAGO--(BUSINESS WIRE)--Celegence, a regulatory compliance service and software solution company, today announced the launch of CAPTIS Copilot, the most advanced document automation and literature review solution for the life sciences industry. CAPTIS Copilot is an enterprise cloud-based platform leveraging pre-trained large language models (LLM) and Reinforcement Learning from Human Feedback (RLHF) for the device and diagnostic industry. This cloud-based solution significantly advances the ability of device and IVD manufacturers to increase innovation and empower clinical, regulatory, and medical writing teams to be more strategic and…

Collaborative Partnership Strengthens Mainz Biomed's Mission to Combat Colorectal Cancer, Saving Lives through Advanced Diagnostics BERKELEY, US – MAINZ, Germany – August 01, 2023 — Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today that London-based Marylebone Laboratory (Marylebone Lab Ltd) has introduced ColoAlert®, Mainz Biomed’s flagship product—a highly effective and user-friendly at-home detection test for colorectal cancer (CRC) - to its extensive UK and international customer base. Further strengthening Mainz Biomed’s global network of esteemed laboratory partners, the collaboration marks another significant milestone in the Company’s mission to combat colorectal ca…

– Gilead expands the ALL4LIVER Grant, Providing Grant Funding to Organizations in Africa, South America, Asia and Oceania, Europe and North America  –  Themed ‘Test. Link. Prioritize’, the Grant Program will Target Projects Focusing on Viral Hepatitis Elimination by 2030 –  SINGAPORE, July 28, 2023 – Gilead Sciences, Inc. (Nasdaq: GILD) today announced the launch of the 2023 Gilead ALL4LIVER Grant, a grant program with the theme of ‘Test. Link. Prioritize’, designed to support innovative projects that drive testing, improve linkage to care and/or elevate viral hepatitis on the public health agenda. The ALL4LIVER Grant will support initiatives around the world (excluding the United States) across hepatitis C, hepatitis B or hepatitis D. Eligible organizations can submit funding applications…

Agreement furthers Alexion’s ambition to transform patient outcomes with genomic medicine and provides synergistic opportunities across AstraZeneca Portfolio includes preclinical gene therapy programmes and enabling technologies with potential across several therapeutic areas Alexion, AstraZeneca Rare Disease, today announced that it has entered a definitive purchase and licence agreement for a portfolio of preclinical gene therapy programmes and enabling technologies from Pfizer Inc. (Pfizer). The agreement furthers Alexion and AstraZeneca’s commitment to advancing next-generation genomic medicines with the addition of complementary pipeline assets and innovative technologies. As part of the agreement, the transaction will bring to Alexion a number of novel adeno-associated virus…

Bracknell, UK, 27th July 2023 – PharmiWeb.Jobs, the world’s premier life science job board, is excited to announce that the platform has now reached over 500,000 registered jobseekers, globally. This remarkable milestone signifies the team’s commitment to connecting life science professionals with the best career opportunities in the industry, whilst helping recruiters and hiring managers locate the top talent they need to drive their organisations forward. “Reaching half a million registered jobseekers is a real testament to the dedication of our team who work so hard to keep us at the forefront of what we do,” said Vincent Lody, Managing Director of PharmiWeb. “We have seen incredible growth over the past few years and look forward to continuing this growth on a truly global scale.” For…

DEERFIELD, Ill. - 2023-07-25 Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced that Vantive will be the name of the company’s proposed spinoff of its Renal Care and Acute Therapies businesses. Vantive is expected to launch as an independent, publicly traded company by July 2024 or earlier, subject to satisfaction of customary conditions.  “Announcing the Vantive name is a critical milestone in our journey to becoming an independent company focused solely on therapies for kidney disease and other vital organ support,” said Chris Toth, executive vice president and group president, Kidney Care at Baxter, who is to serve as chief executive officer of the new company upon spinoff. “The Vantive name reflects our dedicated employees’ steadfast commitment to patients a…

Partnership combines Roche’s proven track record of successfully developing and launching innovative medicines worldwide with Alnylam’s leadership in RNAi therapeutics Zilebesiran, a Phase 2 RNAi therapeutic, has best-in-disease potential for patients with hypertension at high risk of cardiovascular morbidity and mortality, by robustly and durably lowering blood pressure Hypertension, the leading cause of cardiovascular disease, affects more than 1.2 billion adults worldwide. While several therapies exist, a significant unmet need, especially for high risk patients, remains.1 Basel, 24 July 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today a new partnership with Alnylam to develop and commercialise zilebesiran, an investigational RNAi therapeutic currently in Phase 2 for the trea…